Apogee Therapeutics Inc. (APGE)
NASDAQ
Closed
Sep 3, 2026
Day's Range
135.0752 wk Range
35.39Overview - APGE - Apogee Therapeutics Inc.
Key Statistics
Valuation
Enterprise Value
9.22B
P/E (Trailing)
‪-36.11‬
P/E (Forward)
‪-25.99‬
PEG Ratio
‪-13.01‬
Price / Book
‪8.48‬
EV / EBITDA
‪-28.62‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-20.29%‬
Return on Equity
‪-32.45%‬
Ownership
Shares Outstanding
75.33M
Float
58.44M
Short % of Shares Outstanding
‪7.28%‬
Held by Insiders
‪2.31%‬
Held by Institutions
‪110.80%‬
Price stats
Beta
‪0.32‬
50-Day Avg
‪134.18‬
200-Day Avg
‪93.12‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
7 analysts
Average price target
‪$ 134.85‬Shariah Compliance
Report Date: Feb 16, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - APGE - Apogee Therapeutics Inc.
Peers - APGE - Apogee Therapeutics Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- APGENASDAQApogee Therapeutics Inc.10.22BMarket Cap+71.90%52-week change-36.11P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQArgenx SE61.58BMarket Cap+25.27%52-week change37.92P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.32.05BMarket Cap-91.57%52-week change41.68P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE24.13BMarket Cap-2.77%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S15.57BMarket Cap+17.02%52-week change18.34P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.02BMarket Cap+22.62%52-week change-17.62P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.12.37BMarket Cap+15.64%52-week change172.81P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - APGE - Apogee Therapeutics Inc.
About
Apogee Therapeutics Inc. is a clinical-stage biotechnology company focused on developing biologic medicines for immunological and inflammatory diseases. Headquartered in Waltham, Massachusetts and founded in 2022, the company concentrates on validated immunology targets and applies advanced antibody engineering to…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
